<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071225</url>
  </required_header>
  <id_info>
    <org_study_id>ML29167</org_study_id>
    <secondary_id>2013-003388-79</secondary_id>
    <nct_id>NCT02071225</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) + Bendamustine Treatment in Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This phase II trial was designed to evaluate the efficacy of obinutuzumab and bendamustine
      treatment in participants with refractory or relapsed chronic lymphocytic leukemia (CLL).
      Participants receive up to six 28-day cycles of treatment. Treatment consists of intravenous
      (IV) administration of obinutuzumab and bendamustine. Treatment time is expected to last 6
      months, and participant follow-up will last 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 9, 2014</start_date>
  <completion_date type="Anticipated">November 19, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants acheiving Overall Response as assessed by the investigator using the IWCLL 2008 criteria</measure>
    <time_frame>2-3 months after last dose of the study treatment (up to 9 months overall)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants acheiving Best response up to 6 months after treatment assessed by the investigator using the IWCLL 2008 criteria.</measure>
    <time_frame>Approximately 6 months after treatment (up to 12 months overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of progression free survival (PFS) assessed using the IWCLL 2008 criteria</measure>
    <time_frame>From start of treatment up to disease progression or relapse or death, whichever occurred first (up to approximately 2.5 years after last patient first visit [LPFV] overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall survival (OS)</measure>
    <time_frame>Baseline up to death (up to approximately 2.5 years after LPFV overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of event free survival (EFS) assessed using the IWCLL 2008 criteria</measure>
    <time_frame>From start of treatment up to disease progression or relapse or death or start of a new anti-leukemic therapy, whichever occurred first (up to approximately 2.5 years after LPFV overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease free survival (DFS) assessed using the IWCLL 2008 criteria</measure>
    <time_frame>From occurrence of CR up to disease progression or death, whichever occurred first (up to approximately 2.5 years after LPFV overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR) assessed using the IWCLL 2008 criteria</measure>
    <time_frame>From occurrence of CR or PR up to disease progression or death, whichever occurred first (up to approximately 2.5 years after LPFV overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from study start to re-treatment or new therapy</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants without minimal residual disease (MRD-negative), as assessed by flow cytometry</measure>
    <time_frame>Approximately 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>obinutuzmab + bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive obintuzumab and bendamustine in 28-days cycles for a maximum of 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bendamustine</intervention_name>
    <description>70 milligrams per square meter (mg/m^2) given by IV infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.</description>
    <arm_group_label>obinutuzmab + bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>obinutuzumab</intervention_name>
    <description>1000 mg given by intravenous (IV) infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.</description>
    <arm_group_label>obinutuzmab + bendamustine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Diagnosed CD20+ B- chronic lymphocytic leukemia (CLL) according to National Cancer
             Institute (NCI) criteria

          -  Active disease meeting at least 1 of the International Workshop on CLL (IWCLL) 2008
             criteria for treatment

          -  Refractory CLL (i.e. treatment failure or progression during treatment or within 6
             months after the last treatment) or relapse CLL (i.e. participants who met criteria
             for CR or PR, but progressed beyond 6 months post-treatment)

          -  At least 1 prior purine analogue or bendamustine containing therapy

          -  Life expectancy greater than (&gt;) 6 months

          -  Use of effective contraception as described in the study protocol

        Exclusion Criteria:

          -  Prior Alogenic Bone Marrow Transplant

          -  Greater than or equal to (&gt;/=) 3 previous lines of chemotherapy and/or immunotherapy
             for the CLL

          -  Previous obinutuzumab-containing regimen

          -  Treatment failure or progression within 6 months of bendamustine-containing regimen

          -  Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL; Richter's
             transformation) Patients with prolymphocytic transformation cannot entry the study
             either

          -  Active haemolytic anaemia

          -  Inadequate liver function

          -  History of other malignancy which could affect compliance with the protocol or
             interpretation of results. Patients with a history of malignancy that has been treated
             but not with curative intent will be excluded, unless the malignancy has been in
             remission without treatment for &gt;/= 2 years prior to enrolment. Patients with a
             history of adequately treated carcinoma in situ of the cervix; basal or squamous cell
             skin cancer; low grade, early stage localized prostate cancer treated surgically with
             curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated
             with lumpectomy alone with curative intent are eligible

          -  Evidence of significant, uncontrolled concomitant diseases that could affect
             compliance with the protocol or interpretation of results, including significant
             cardiovascular disease or pulmonary disease

          -  Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for
             diagnosis

          -  Regular treatment with corticosteroids during the 4 weeks prior to study start, unless
             administered for another condition at a dose equivalent to less trhan or equal to
             (&lt;/=) 30 milligrams per day (mg/day) prednisone

          -  Known active infection or any infection requiring treatment with IV antibiotics or
             hospitalization within 4 weeks prior to study start

          -  Patients with HIV, human T cell leukemia virus 1 (HTLV-1), hepatitis B or hepatitis C

          -  Pregnancy or breast-feeding

          -  Vaccination with a live vaccine within 4 weeks prior to baseline visit

          -  Receipt of any other study drug within 4 weeks prior to study start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital De Txagorritxu; Servicio de Hematologia</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche; Servicio de Hematologia</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cabueñes; Servicio de Hematología y Hemoterapia</name>
      <address>
        <city>Gijon</city>
        <state>Asturias</state>
        <zip>33203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Central de Asturias; servicio de Hematologia</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08915</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa; Servicio de Hematologia</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra, Servicio de Hematología</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Hematologia</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto; Servicio de Hematologia</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial; Servicio de Hematología y Oncología</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Castellon; Servicio de Hematologia</name>
      <address>
        <city>Castellon</city>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia; Servicio de Hematologia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves; Servicio de Hematologia</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Gran Canaria Dr. Negrin; Servicio de Hematologia</name>
      <address>
        <city>Las Palmas</city>
        <zip>35020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz; Servicio de Hematologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Paz; Servicio de Hematologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio Hematologia</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro; Servicio de Hematologia</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol; Servicio de Hematologia</name>
      <address>
        <city>Malaga</city>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Ourense, Servicio de Hematologia</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena; Servicio de Hematologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Nuestra Señora de Valme; Servicio de Hematologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset; Servicio de Hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa; Servicio de Hematologia</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

